Anixa Biosciences Administers Second Dose To Patient In Ovarian Cancer CAR-T Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Anixa Biosciences has administered a second dose to a patient in its ovarian cancer CAR-T clinical trial. The patient showed positive clinical activity after the initial treatment, with necrosis, inflammation, and T cell infiltration observed in the tumor biopsy.
October 15, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anixa Biosciences administered a second dose in its ovarian cancer CAR-T trial, showing positive clinical activity in the patient.
The administration of a second dose and the observed positive clinical activity in the patient are significant milestones in Anixa Biosciences' clinical trial. This progress could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90